Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Objectives: Switching at Low HIV-...

Full description

Bibliographic Details
Main Authors: Paula Munderi, Edwin Were, Anchalee Avihingsanon, Pascale A.M Mbida, Lerato Mohapi, Samba B. Moussa, Marjolein Jansen, Ceyhun Bicer, Perry Mohammed, Yvon van Delft
Format: Article
Language:English
Published: AOSIS 2019-07-01
Series:Southern African Journal of HIV Medicine
Subjects:
LMIC
Single-Tablet-Regimen
Virologically suppressed adults
Treatment-emergent Resistance
SALIF
Online Access:https://sajhivmed.org.za/index.php/hivmed/article/view/949

Internet

https://sajhivmed.org.za/index.php/hivmed/article/view/949

Similar Items